EN DE
Watch Optimi Health Corp. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Optimi Health Corp. (OPTH) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Optimi Health Corp. stock $1.45, price $2.15, that is 32.6% below the price, quality 26 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Canada · ISIN CA68405H3080

OH Optimi Health Corp. logo Thin data Nov 17, 2026

Optimi Health Corp.

OPTH · US

Expensive (fair value 33% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Expensive Growth (revenue 3y +74.2 %/yr in CAD) 
Revenue last quarter 29% below a year ago. 
Fair value $1.45 · Overvalued 
Quality 26/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (0/6) 
Narrow moat 9/100
Thin data 
Estimate
Watch Optimi Health Corp. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.74 $2.11 Fair Value $1.45 Apr 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.

How to read this chart

60‑month range $2.11 – $23.74 · fair‑value band $1.09 – $1.82 · the $2.15 price screens above the $1.45 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.

Follow Optimi Health in your weekly email

Every Wednesday you see whether Optimi Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Optimi Health Corp. operates as a pharmaceutical and nutraceutical drug manufacturing company in Canada. The company manufactures controlled substances including finished MDMA and psilocybin drug products, supplying them directly to authorized clinics, pharmacies, clinical trials, and partners.

Show moreShow less

The company produces and supplies MDMA, natural psilocybin, psilocin, other psychedelic substances, and functional mushrooms derived from botanical sources for health and wellness markets.

The company also engages in farming, processing, and distribution of raw mushroom biomass, mushroom extracts, manufacturing of drug products, and mushroom supplements. It sells its products through Amazon marketplace and distributors/brokers, as well as online.

Optimi Health Corp. was incorporated in 2020 and is based in Princeton, Canada.

Stock analysis

Optimi Health Corp. (OPTH) currently trades at $2.15, while our estimate is $1.45, 33% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.09 (bear) to $1.82 (bull), the price of $2.15 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 26/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Optimi Health Corp. reported revenue of C$427K in FY2025 versus C$80.7K in FY2022, a compound +74.2%/yr. Reported net income was −C$3.7M in FY2025.

Key figures

Market cap $12.3M Micro · P/S ratio 70.1 · EPS (TTM) $−1.56 · Return on equity −54.4% · Return on assets (EBIT) −31.4% (5-year average) · Operating margin −2,926% · Revenue (TTM) C$176K · Revenue growth (YoY) −28.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).

What moves the price

The share trades about 75% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −33%, OPTH screens richer than that median.

Fair Value

Bear $1.09 Fair Value $1.45 Bull $1.82
Price $2.15 · Downside -32.6%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 26/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 60
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 46
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 8
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+9.5%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+74.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8,219.5% (2022) → −1,062.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

OPTH screens overvalued: fair value 33% below the price. Compare with Merck KGaA →

Compare Optimi Health Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 26 · Bottom 25%
Fair Value upside −32.6% · Below median
Profitability
Return on assets −24.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −28.6% · Bottom 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 2.68× · Pricier than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $84.39 $113.53 +35% vs OPTH
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.02 ¥53.04 +10% vs OPTH
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,868 ₹1,983 +6% vs OPTH
Haleon plc HLN $9.20 $8.47 −8% vs OPTH
Merck KGaA MRK €149.70 €108.83 −27% vs OPTH
Galderma Group GALD CHF 191.00 CHF 112.46 −41% vs OPTH
Takeda Pharmaceutical Company TAK $21.59 $11.23 −48% vs OPTH
Teva Pharmaceutical Industries Limited TEVA $42.57 $20.74 −51% vs OPTH
Sandoz Group SDZ CHF 84.60 CHF 40.54 −52% vs OPTH
Divi's Laboratories Limited DIVISLAB ₹11,080 ₹1,567 −86% vs OPTH

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Optimi Health Corp.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Optimi Health Corp. Fair Value". https://www.fairvalue-calculator.com/stock/OPTH

Frequently asked questions

Is Optimi Health Corp. (OPTH) overvalued or undervalued?
As of Nov 17, 2026, our estimate of fair value is $1.45 versus a price of $2.15, about 33% lower (overvalued).
What is the fair value of OPTH?
Our estimate for Optimi Health Corp. is $1.45 (as of Nov 17, 2026), built from audited fundamentals. The current price: $2.15.
What is the quality score of OPTH?
Optimi Health Corp. has a Quality Score of 26/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Optimi Health Corp. (OPTH)?
Our calculated price target is the estimate of $1.45 (as of Nov 17, 2026). Cautious scenario $1.09, optimistic scenario $1.82. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Optimi Health Corp. stock forecast for 2026?
Our estimate puts fair value at $1.45, about 33% lower versus a price of $2.15 (overvalued). Cautious scenario $1.09, optimistic scenario $1.82. The calculation is refreshed regularly with new filings.
What is the revenue of Optimi Health Corp. (OPTH)?
Optimi Health Corp. reported trailing-twelve-month revenue of about C$176K (latest available figure, as of Nov 17, 2026).
What is the intrinsic value of Optimi Health Corp. (OPTH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Optimi Health Corp. it is $1.45 per share (as of Nov 17, 2026), against a price of $2.15.
Is Optimi Health Corp. stock overvalued or undervalued in 2026?
As of Nov 17, 2026, OPTH trades above its calculated fair value: price $2.15, fair value $1.45, a gap of about −33% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of OPTH?
No. The price is what the market pays today ($2.15); the fair value is what the company's own numbers justify ($1.45). For Optimi Health Corp. the two are $0.7000 per share apart. That gap is exactly why we show both numbers side by side.
How much is Optimi Health Corp. worth?
The market values Optimi Health Corp. at about $12.3M (market capitalisation, as of Nov 17, 2026). Per share that is $2.15; our models calculate a fair value of $1.45 per share.
What do the bullish and bearish scenarios say about OPTH?
Our models span a range for Optimi Health Corp.: cautious scenario $1.09, base $1.45, optimistic $1.82 per share (as of Nov 17, 2026, price $2.15). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Optimi Health Corp. (OPTH)?
Balance-sheet figures for Optimi Health Corp. (as of Nov 17, 2026): return on equity −54.4%. They feed the Quality Score of 26/100, which measures business quality independently of the share price.
How far is OPTH from its 52-week high?
Optimi Health Corp. trades at $2.15, about 75% below its 52-week high of $8.49 and 2% above the low of $2.11 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $1.45 is for.
Which stocks are comparable to Optimi Health Corp.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Optimi Health Corp. stock attractive at the current price?
The data as of Nov 17, 2026: price $2.15, calculated fair value $1.45 (−33%), Quality Score 26/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Optimi Health Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Optimi Health Corp. (OPTH)?
The closing price on Nov 16, 2026 was $2.15. Our estimate is $1.45, about 33% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Optimi Health Corp. right now?
The price sits above even our optimistic bull case ($1.82). The favourable scenario is already priced in. Weak quality (26/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Optimi Health Corp.

How large is the market capitalisation of Optimi Health Corp. (OPTH)?
The market capitalisation of Optimi Health Corp. is $12.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Optimi Health Corp. (OPTH)?
The price-to-sales ratio of Optimi Health Corp. is 70.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Optimi Health Corp. (OPTH)?
Earnings per share at Optimi Health Corp. are $−1.56. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Optimi Health Corp. (OPTH)?
The return on equity (ROE) of Optimi Health Corp. is −54.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Optimi Health Corp. (OPTH)?
On an EBIT basis the return on assets of Optimi Health Corp. is −31.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Optimi Health Corp. (OPTH)?
The operating margin of Optimi Health Corp. is −2,926% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Optimi Health Corp. (OPTH)?
Revenue at Optimi Health Corp. is down 28.6% versus a year earlier (3y avg +74.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Optimi Health Corp. (OPTH) generate?
The free cash flow of Optimi Health Corp. is −C$2.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Optimi Health Corp. (OPTH) carry?
The net debt of Optimi Health Corp. is C$5.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Optimi Health Corp. in the live analysis

One click puts Optimi Health Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.